BJMO - 2025, issue SPECIAL, june 2025
Tamara Verbeek MSc, Jolien Blokken PhD, PharmD
Up to 50% of the patients with non-small cell lung cancer (NSCLC) have actionable genomic alterations (AGAs), driving the use of targeted therapies. Over the past decade, antibody-drug conjugates (ADCs) -combining a monoclonal antibody, linker, and potent cytotoxic drug to selectively target cancer cells- have emerged as a promising treatment option. This article reviews the available evidence regarding the efficacy and safety of ADCs in patients with NSCLC harbouring AGAs.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
